

8 July 2021

**Diaceutics PLC**  
**("Diaceutics" or the "Group" or the "Company")**

**Trading update for the six months ended 30 June 2021**

Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, announces a trading update for the six months ended 30 June 2021 (the "Period").

The Group has delivered a strong start to the 2021 financial year, in line with management's expectations, against the backdrop of the continuing global COVID-19 pandemic, reflecting the growing momentum in the business following the launch of the DXRX platform on 28 October 2020.

The Group expects to report revenue growth of approximately 13% to £6.0 million <sup>1</sup> (H1 2020: £5.3 million), being 24% on a constant currency basis. The Group continues to invest in the development of the DXRX platform and closed the Period with net cash of £23.7 million <sup>1</sup> (H1 2020: £29.8 million), in line with the Board's expectations.

At the start of the year, the Board set a target for 20% of full year revenue to be generated via the DXRX platform. The Group delivered revenue from 25 projects via the platform, representing over 30% of revenue in the Period.

**Peter Keeling, CEO and Founder of Diaceutics commented:**

*"I am pleased to report a positive trading performance in the first half of the year, demonstrating the growing momentum in the business following the successful launch of the DXRX platform last year. We are seeing clear evidence of its value to stakeholders within the Pharma industry and to Diaceutics, providing us with the ability to scale our offering in line with the increased growth in the precision medicine industry. We remain confident that we are on the path towards becoming a strategically embedded platform provider to the Pharma industry."*

**Notice of Results**

The Group's interim results for the six months ending 30 June 2021 are expected to be announced on 14 September 2021.

<sup>1</sup> Revenue and Net Cash figures are unaudited

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014. The person responsible for release of this announcement on behalf of the Company is Philip White (Chief Financial Officer).

**Enquiries:**

**Diaceutics PLC**

Philip White, Chief Financial Officer

Via Alma PR

**Stifel Nicolaus Europe Limited (Nomad & Broker)**

Ben Maddison  
Stewart Wallace  
Nick Adams

Tel: +44 (0)20 7710 7600

**Alma PR**

Caroline Forde  
Robyn Fisher  
Kieran Breheny

Tel: +44(0)20 3405 0205  
diaceutics@almapr.co.uk

**About Diaceutics**

At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network®.

DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world

diagnostic testing data from a global network of laboratories.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

TSTUPUWCMUPGGRM